- Home
- NVCR
NVCR
NovoCure Limited
as of 12-05-2025 3:46pm EST
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
| Founded: | 2000 | Country: | Switzerland |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 1.3B | IPO Year: | 2015 |
| Target Price: | $28.42 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.70 - $34.13 | Next Earning Date: | 10-30-2025 |
| Revenue: | $642,269,000 | Revenue Growth: | 11.17% |
| Revenue Growth (this year): | 9.75% | Revenue Growth (next year): | 5.62% |
AI-Powered NVCR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare NVCR vs Leading Stocks
See how NVCR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.